Loading...
Loading...
Cardiome Pharma Corp.
CRMECOM and Merck
MRK, known as MSD outside the United States and Canada, today announced
that Merck will return the global marketing and development rights for both
the intravenous (IV) and oral formulations for vernakalant to Cardiome.
Vernakalant IV is marketed, in certain countries, under the brand name
BRINAVESS.^TM BRINAVESS was approved in the European Union on September 1,
2010 for the rapid conversion of recent onset atrial fibrillation (AF) to
sinus rhythm in adults: for non-surgery patients with AF of seven days or less
and for post-cardiac surgery patients with AF of three days or less.
Vernakalant IV is not approved for use in the United States or Canada.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in